Do analysts rate NVO or TAK?

Novo Nordisk A/S presently has a consensus target price of $65.81, suggesting a potential upside of 40.18%. Given Novo Nordisk A/S's higher possible upside, equities analysts plainly believe Novo Nordisk A/S is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novo Nordisk A/S 1 Sell rating(s) 15 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.19 Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media refer more to NVO or TAK?

In the previous week, Novo Nordisk A/S had 77 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 84 mentions for Novo Nordisk A/S and 7 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.94 beat Novo Nordisk A/S's score of 0.18 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 30 Very Positive mention(s) 20 Positive mention(s) 10 Neutral mention(s) 15 Negative mention(s) 7 Very Negative mention(s) Neutral Takeda Pharmaceutical 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer PFE or TAK?

Pfizer currently has a consensus price target of $28.28, indicating a potential upside of 7.14%. Given Pfizer's higher possible upside, equities research analysts plainly believe Pfizer is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pfizer 2 Sell rating(s) 14 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.19 Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media refer more to PFE or TAK?

In the previous week, Pfizer had 78 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 85 mentions for Pfizer and 7 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.94 beat Pfizer's score of 0.48 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 31 Very Positive mention(s) 12 Positive mention(s) 28 Neutral mention(s) 12 Negative mention(s) 0 Very Negative mention(s) Neutral Takeda Pharmaceutical 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate TAK or BMY?

Bristol Myers Squibb has a consensus target price of $66.06, suggesting a potential upside of 2.59%. Given Bristol Myers Squibb's stronger consensus rating and higher possible upside, analysts clearly believe Bristol Myers Squibb is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Bristol Myers Squibb 1 Sell rating(s) 11 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.52

Does the media prefer TAK or BMY?

In the previous week, Bristol Myers Squibb had 51 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 58 mentions for Bristol Myers Squibb and 7 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.94 beat Bristol Myers Squibb's score of 0.39 indicating that Takeda Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bristol Myers Squibb 13 Very Positive mention(s) 15 Positive mention(s) 21 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts rate TAK or GSK?

GSK has a consensus target price of $53.00, indicating a potential upside of 0.42%. Given GSK's higher possible upside, analysts clearly believe GSK is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 GSK 2 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.10

Which has better valuation & earnings, TAK or GSK?

GSK has higher revenue and earnings than Takeda Pharmaceutical. GSK is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Takeda Pharmaceutical $28.32B 1.97 -$1.01B $0.34 51.34 GSK $43.07B 2.48 $7.54B $3.20 16.49

Does the media prefer TAK or GSK?

In the previous week, Takeda Pharmaceutical and Takeda Pharmaceutical both had 7 articles in the media. Takeda Pharmaceutical's average media sentiment score of 0.94 beat GSK's score of 0.58 indicating that Takeda Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GSK 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TAK or SNY?

Sanofi has a consensus target price of $49.50, suggesting a potential upside of 13.72%. Given Sanofi's stronger consensus rating and higher possible upside, analysts clearly believe Sanofi is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Sanofi 1 Sell rating(s) 9 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.40

Does the media prefer TAK or SNY?

In the previous week, Sanofi had 6 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 13 mentions for Sanofi and 7 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.94 beat Sanofi's score of 0.92 indicating that Takeda Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanofi 6 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Takeda Pharmaceutical (TAK) Competitors

$17.45 +0.44 (+2.56%)

As of 11:31 AM Eastern

Compare

TAK vs. NVO, PFE, BMY, GSK, and SNY

Should you buy Takeda Pharmaceutical stock or one of its competitors? MarketBeat compares Takeda Pharmaceutical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Takeda Pharmaceutical include Novo Nordisk A/S (NVO), Pfizer (PFE), Bristol Myers Squibb (BMY), GSK (GSK), and Sanofi (SNY). These companies are all part of the "pharmaceuticals" industry.

How does Takeda Pharmaceutical compare to Novo Nordisk A/S?

Novo Nordisk A/S (NYSE:NVO) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

Novo Nordisk A/S presently has a consensus target price of $65.81, suggesting a potential upside of 40.18%. Given Novo Nordisk A/S's higher possible upside, equities analysts plainly believe Novo Nordisk A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	15 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.19
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Novo Nordisk A/S had 77 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 84 mentions for Novo Nordisk A/S and 7 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.94 beat Novo Nordisk A/S's score of 0.18 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	30 Very Positive mention(s)	20 Positive mention(s)	10 Neutral mention(s)	15 Negative mention(s)	7 Very Negative mention(s)	Neutral
Takeda Pharmaceutical	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Novo Nordisk A/S has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.08, meaning that its stock price is 108% less volatile than the broader market.

Novo Nordisk A/S has higher revenue and earnings than Takeda Pharmaceutical. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.48	$15.51B	$4.09	11.48
Takeda Pharmaceutical	$28.32B	1.97	-$1.01B	$0.34	51.34

Novo Nordisk A/S has a net margin of 35.36% compared to Takeda Pharmaceutical's net margin of 3.80%. Novo Nordisk A/S's return on equity of 61.20% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	35.36%	61.20%	21.49%
Takeda Pharmaceutical	3.80%	10.95%	5.34%

Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.7%. Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.7%. Novo Nordisk A/S pays out 42.8% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Novo Nordisk A/S beats Takeda Pharmaceutical on 15 of the 18 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to Pfizer?

Pfizer (NYSE:PFE) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Pfizer has a net margin of 6.80% compared to Takeda Pharmaceutical's net margin of 3.80%. Pfizer's return on equity of 19.63% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	6.80%	19.63%	8.46%
Takeda Pharmaceutical	3.80%	10.95%	5.34%

Pfizer currently has a consensus price target of $28.28, indicating a potential upside of 7.14%. Given Pfizer's higher possible upside, equities research analysts plainly believe Pfizer is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

68.4% of Pfizer shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 0.6% of Pfizer shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Pfizer has higher revenue and earnings than Takeda Pharmaceutical. Pfizer is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.40	$7.77B	$0.76	34.73
Takeda Pharmaceutical	$28.32B	1.97	-$1.01B	$0.34	51.34

In the previous week, Pfizer had 78 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 85 mentions for Pfizer and 7 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.94 beat Pfizer's score of 0.48 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	31 Very Positive mention(s)	12 Positive mention(s)	28 Neutral mention(s)	12 Negative mention(s)	0 Very Negative mention(s)	Neutral
Takeda Pharmaceutical	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pfizer has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.08, meaning that its share price is 108% less volatile than the broader market.

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.5%. Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.7%. Pfizer pays out 226.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has raised its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Pfizer beats Takeda Pharmaceutical on 16 of the 20 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to Bristol Myers Squibb?

Takeda Pharmaceutical (NYSE:TAK) and Bristol Myers Squibb (NYSE:BMY) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Bristol Myers Squibb has a consensus target price of $66.06, suggesting a potential upside of 2.59%. Given Bristol Myers Squibb's stronger consensus rating and higher possible upside, analysts clearly believe Bristol Myers Squibb is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Bristol Myers Squibb	1 Sell rating(s)	11 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.52

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Takeda Pharmaceutical has a beta of -0.08, suggesting that its stock price is 108% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market.

In the previous week, Bristol Myers Squibb had 51 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 58 mentions for Bristol Myers Squibb and 7 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.94 beat Bristol Myers Squibb's score of 0.39 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bristol Myers Squibb	13 Very Positive mention(s)	15 Positive mention(s)	21 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral

Bristol Myers Squibb has higher revenue and earnings than Takeda Pharmaceutical. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.97	-$1.01B	$0.34	51.34
Bristol Myers Squibb	$49.19B	2.67	$7.05B	$4.54	14.18

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.7%. Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 3.9%. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol Myers Squibb pays out 55.5% of its earnings in the form of a dividend. Bristol Myers Squibb has increased its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Bristol Myers Squibb has a net margin of 18.87% compared to Takeda Pharmaceutical's net margin of 3.80%. Bristol Myers Squibb's return on equity of 66.90% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	3.80%	10.95%	5.34%
Bristol Myers Squibb	18.87%	66.90%	14.74%

Summary

Bristol Myers Squibb beats Takeda Pharmaceutical on 18 of the 20 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to GSK?

Takeda Pharmaceutical (NYSE:TAK) and GSK (NYSE:GSK) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

In the previous week, Takeda Pharmaceutical and Takeda Pharmaceutical both had 7 articles in the media. Takeda Pharmaceutical's average media sentiment score of 0.94 beat GSK's score of 0.58 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.7%. GSK pays an annual dividend of $1.79 per share and has a dividend yield of 3.4%. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GSK pays out 55.9% of its earnings in the form of a dividend. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

Takeda Pharmaceutical has a beta of -0.08, suggesting that its share price is 108% less volatile than the broader market. Comparatively, GSK has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market.

GSK has higher revenue and earnings than Takeda Pharmaceutical. GSK is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.97	-$1.01B	$0.34	51.34
GSK	$43.07B	2.48	$7.54B	$3.20	16.49

GSK has a net margin of 14.56% compared to Takeda Pharmaceutical's net margin of 3.80%. GSK's return on equity of 43.23% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	3.80%	10.95%	5.34%
GSK	14.56%	43.23%	11.60%

GSK has a consensus target price of $53.00, indicating a potential upside of 0.42%. Given GSK's higher possible upside, analysts clearly believe GSK is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
GSK	2 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.10

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by company insiders. Comparatively, 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

GSK beats Takeda Pharmaceutical on 14 of the 18 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to Sanofi?

Takeda Pharmaceutical (NYSE:TAK) and Sanofi (NASDAQ:SNY) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.7%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.0%. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Sanofi is clearly the better dividend stock, given its higher yield and lower payout ratio.

Sanofi has higher revenue and earnings than Takeda Pharmaceutical. Sanofi is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.97	-$1.01B	$0.34	51.34
Sanofi	$49.35B	2.14	$8.84B	$1.91	22.79

Takeda Pharmaceutical has a beta of -0.08, suggesting that its stock price is 108% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

Sanofi has a consensus target price of $49.50, suggesting a potential upside of 13.72%. Given Sanofi's stronger consensus rating and higher possible upside, analysts clearly believe Sanofi is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Sanofi	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.40

Sanofi has a net margin of 8.66% compared to Takeda Pharmaceutical's net margin of 3.80%. Sanofi's return on equity of 14.19% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	3.80%	10.95%	5.34%
Sanofi	8.66%	14.19%	7.95%

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Sanofi had 6 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 13 mentions for Sanofi and 7 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.94 beat Sanofi's score of 0.92 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanofi	6 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sanofi beats Takeda Pharmaceutical on 17 of the 19 factors compared between the two stocks.

Get Takeda Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TAK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TAK vs. The Competition

Export

Metric	Takeda Pharmaceutical	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$55.96B	$11.87B	$6.99B	$24.10B
Dividend Yield	2.88%	2.71%	2.59%	3.70%
P/E Ratio	51.37	789.74	270.87	30.35
Price / Sales	1.97	994.92	670.81	12.83
Price / Cash	5.39	72.59	71.89	33.22
Price / Book	1.17	10.79	13.17	6.90
Net Income	-$1.01B	$2.78B	$3.45B	$1.06B
7 Day Performance	2.11%	3.56%	4.26%	2.75%
1 Month Performance	2.95%	-1.41%	-1.90%	2.42%
1 Year Performance	21.34%	192.77%	76.72%	20.09%

Takeda Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TAK Takeda Pharmaceutical	2.2351 of 5 stars	$17.46 +2.6%	N/A	+19.1%	$55.96B	$28.32B	51.37	47,000	Analyst Upgrade Gap Up
NVO Novo Nordisk A/S	4.2142 of 5 stars	$47.12 +0.1%	$65.56 +39.2%	+1.3%	$210.21B	$46.80B	11.06	69,505	Trending News Earnings Report Dividend Cut Analyst Upgrade Gap Up
PFE Pfizer	3.8302 of 5 stars	$25.05 +0.2%	$28.50 +13.8%	+9.3%	$142.54B	$62.58B	19.12	75,000	Trending News Earnings Report Analyst Forecast
BMY Bristol Myers Squibb	4.1157 of 5 stars	$65.45 +0.2%	$63.59 -2.8%	+43.2%	$133.37B	$49.19B	14.42	32,500	Analyst Upgrade High Trading Volume
GSK GSK	2.5322 of 5 stars	$51.52 -0.3%	$53.00 +2.9%	+41.8%	$104.55B	$43.07B	16.11	66,841	Dividend Cut

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:TAK) was last updated on 8/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Takeda Pharmaceutical (TAK) Competitors

TAK vs. NVO, PFE, BMY, GSK, and SNY

How does Takeda Pharmaceutical compare to Novo Nordisk A/S?

Summary

How does Takeda Pharmaceutical compare to Pfizer?

Summary

How does Takeda Pharmaceutical compare to Bristol Myers Squibb?

Summary

How does Takeda Pharmaceutical compare to GSK?

Summary

How does Takeda Pharmaceutical compare to Sanofi?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAK vs. The Competition

Takeda Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Takeda Pharmaceutical (TAK) Competitors

TAK vs. NVO, PFE, BMY, GSK, and SNY

How does Takeda Pharmaceutical compare to Novo Nordisk A/S?

Do analysts rate NVO or TAK?

Does the media refer more to NVO or TAK?

Do insiders & institutionals have more ownership in NVO or TAK?

Which has more risk & volatility, NVO or TAK?

Which has better earnings & valuation, NVO or TAK?

Is NVO or TAK more profitable?

Is NVO or TAK a better dividend stock?

Summary

How does Takeda Pharmaceutical compare to Pfizer?

Is PFE or TAK more profitable?

Do analysts prefer PFE or TAK?

Do institutionals and insiders hold more shares of PFE or TAK?

Which has preferable earnings and valuation, PFE or TAK?

Does the media refer more to PFE or TAK?

Which has more risk and volatility, PFE or TAK?

Is PFE or TAK a better dividend stock?

Summary

How does Takeda Pharmaceutical compare to Bristol Myers Squibb?

Do analysts rate TAK or BMY?

Do insiders and institutionals hold more shares of TAK or BMY?

Which has more risk and volatility, TAK or BMY?

Does the media prefer TAK or BMY?

Which has better earnings and valuation, TAK or BMY?

Is TAK or BMY a better dividend stock?

Is TAK or BMY more profitable?

Summary

How does Takeda Pharmaceutical compare to GSK?

Does the media prefer TAK or GSK?

Is TAK or GSK a better dividend stock?

Which has more volatility & risk, TAK or GSK?

Which has better valuation & earnings, TAK or GSK?

Is TAK or GSK more profitable?

Do analysts rate TAK or GSK?

Do insiders and institutionals hold more shares of TAK or GSK?

Summary

How does Takeda Pharmaceutical compare to Sanofi?

Is TAK or SNY a better dividend stock?

Which has stronger earnings & valuation, TAK or SNY?

Which has more risk and volatility, TAK or SNY?

Do analysts prefer TAK or SNY?

Is TAK or SNY more profitable?

Do insiders and institutionals believe in TAK or SNY?

Does the media prefer TAK or SNY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAK vs. The Competition

Takeda Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools